MA-VERACODE
2.4.2024 09:31:35 CEST | Business Wire | Press release
Veracode, a global leader in application risk management, today announced the acquisition of Longbow Security, a pioneer in security risk management for cloud-native environments. The acquisition marks the next exciting phase of Veracode, underscoring the company’s commitment to help organizations effectively manage and reduce application risk across the growing attack surface.
The integration of Longbow into Veracode enables security teams to discover cloud and application assets quickly and easily assess their threat exposure using automated issue investigation and root cause analysis. Longbow provides a centralized view of risk for cloud assets and applications, thereby simplifying complex workflows, enabling faster and more effective remediation, and improving overall security posture. The result is reduced risk and fewer vulnerabilities in applications and cloud infrastructures.
Increased adoption of cloud infrastructure, combined with developers taking on more responsibility for the creation, deployment, and security of software, has introduced operational complexity. Organizations now require a deeper understanding of their risk profile within changing environments and a continuous security feedback loop throughout the software development life cycle.
“Security teams are drowning in alerts that lack sufficient detail on the level of business risk, degree of exploitability of a flaw, and specific code-level insight to keep pace with remediation requirements. As a result, risk continues to accumulate,” said Brian Roche, Chief Product Officer at Veracode. “With the combination of Veracode and Longbow, teams can get a comprehensive view of their risk, automate prioritization of what matters most, and, with Veracode Fix, automate remediation of code security flaws.”
Longbow and Veracode Simplify Cloud Application Security for Overloaded Teams
With 71 percent of organizations shouldering the burden of “security debt” (flaws in applications that remain unfixed for one year), teams must act quickly to reduce their threat exposure. Yet, sufficient visibility and alert fatigue continue to plague cloud and application security professionals today. With Longbow, Veracode customers can address these challenges in four ways:
- Unified visibility of risk across applications, code, and cloud. This gives teams insight to tackle significant issues that matter most to the business.
- Orchestrated remediation from code to cloud, enabling teams to prioritize and remediate with Veracode’s AI-driven fix capabilities.
- Actionable insights with ‘Best Next Action’ advice, so customers can conduct a root cause analysis and pinpoint the best path to remediation.
- Continuous monitoring and assessment via real-time vulnerability discovery across application portfolios and runtime environments, meaning customers know exactly what is running and where.
Derek Maki, Co-Founder & Chief Product Officer at Longbow said, “We founded Longbow with a mission to simplify an increasingly complex application security risk management process and help organizations reduce risk at scale. By joining forces with Veracode, our combined solutions provide unmatched visibility, automation, and remediation capability for security and engineering teams. We are excited to take cloud-native application security to the next level.”
“This is the perfect fit for Longbow,” said Dayne Myers, Co-founder & Chief Executive Officer of Longbow. “After careful consideration, we believe that our technology and team align seamlessly with Veracode's vision, making this the best choice for Longbow’s future."
“We’re thrilled to welcome Longbow to Veracode and expand our platform capabilities with industry-leading application security posture management for today’s enterprise requirements,” closed Sam King, Chief Executive Officer at Veracode. “The integration of our solutions provides organizations with a holistic application risk management platform that spans code to cloud. Veracode combined with Longbow advances the field of application security and enables customers to secure their increasingly complex application landscape more efficiently.”
Longbow is available immediately. To learn more about the platform, visit the Longbow website. Read the blog for information on the acquisition.
About Veracode
Veracode is intelligent software security. The Veracode Software Security Platform continuously finds flaws and vulnerabilities at every stage of the modern software development lifecycle. Using powerful AI trained on a carefully curated, trusted dataset from experience analyzing trillions of lines of code, Veracode customers fix flaws faster with high accuracy. Trusted by security teams, developers, and business leaders from thousands of the world’s leading organizations, Veracode is the pioneer, continuing to redefine what intelligent software security means.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and Twitter.
Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401671481/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
